Introduction
Adenovirus is an important human pathogen, estimated to cause 8% of clinically relevant viral disease globally (1) . Human adenoviruses (HAdV) are divided into 51 serotypes (HAdV-1 -HAdV-51) based on type-specific antiserum-mediated neutralization of infectivity, and into six species, also referred to as subgenera or subgroups (HAdV-A, B, C, D, E, and F) based on hemagluttination inhibition (HI) (2) . HAdV-B is further classified into subspecies B1 and B2.
Serotype is determined primarily by the hexon coat protein, while HI is determined primarily by the receptor-binding fiber protein. In civilian populations, HAdV-B1 serotypes 3, 7, 16, 21, and 50, HAdV-E serotype 4, and one member of the otherwise gastric species HAdV-B2 (serotype 14) are known to cause outbreaks of illness ranging from mild febrile respiratory infections and conjunctivitis to potentially lethal disseminated infections in both adults and children (3) .
HAdV-C serotypes 1, 2, 5 and 6 cause widespread upper respiratory infections in infants and children (4) , and occasional outbreaks in adults. Other HAdV species are usually not associated with respiratory disease in otherwise healthy humans.
HAdV seems to have found a particularly destructive niche in military training camps.
HAdV-B1 serotypes 3, 7, and 21, HAdV-E serotype 4, and HAdV-B2 serotype 14 have been identified as the causal agents in severe outbreaks of acute respiratory disease (ARD) among military recruits in training centers (5, 6) . Prior to the initiation of an HAdV vaccination program in 1971, outbreaks occurred regularly during which approximately one out of six recruits in affected camps required hospitalization (1) . Systematic vaccination of recruits against the two most common agents of ARD in the military, HAdV-4 and HAdV-7, decreased HAdVspecific respiratory illness by 95-99% and overall respiratory illness rates by 50-60% (7) .
Despite this general efficacy, vaccine breakthrough (infection of vaccinated individuals by the targeted pathogen) was still regularly reported (2) . Production of the vaccine was suspended in 1996, at which point vaccination became sporadic until the existing stocks ran out in 1999. ARD rates quickly returned to prevaccine levels, with HAdV as the apparent causal agent, and reintroduction of the vaccine is being actively pursued (2) .
To explore the possibility that unique HAdV strains were causing ARD in vaccinated individuals, throat swab samples were selected from the Naval Health Research Center (NHRC) population-based febrile respiratory illness (FRI) surveillance collection from vaccinated (N = 21) and unvaccinated (N = 31) recruits who reported with ARD between 1996 and 2000.
Samples were chosen that had previously tested positive for HAdV-4 or HAdV-7 by culture and serotypic antibody neutralization. The gene coding for the primary adenoviral antigen, the hexon coat protein, was sequenced from these isolates. The sequence data suggested that the detectable HAdV-4 and HAdV-7 strains apparently responsible for vaccine breakthrough were the same as those circulating in unvaccinated military and civilian populations (2) . In this study we reanalyze the same set of samples, using newly emerging technologies capable of resolving complex concurrent coinfections of multiple HAdV strains, to address the possibility that breakthrough is facilitated by coinfection.
Results

Methods of detection.
The methods used here, including a recently developed 70-mer spotted microarray (8), a commercially available multiplex PCR-ELISA assay (Adenovirus Consensus kit; Argene Inc., North Massapequa, New York, USA), and a published species-specific multiplex PCR assay (9), used here as both a multiplex and as a parallel series of separate monoplex PCR tests, can all specifically assay for the presence of more than one adenoviral strain at once. Although they vary in the degree to which signals from multiple strains or species will interfere with each other and in the breadth and specificity of their coverage, these tests can yield measurable signals from "secondary" (less numerous) coinfectants against the background of stronger signals produced by "primary" infecting strains. Using these three methods, data profiles for each of the 52 samples were generated. Two representative profiles, from vaccinated sample #7274 and unvaccinated sample #10756, are presented in Figure 1 . Many of the positive results from these tests were further verified by comparison with results from independent methods such as microneutralization, hexon sequence analysis, serotype-specific PCR (using primers not used in the multiplex tests -see Table 3 ), and sequencing of PCR amplicons. The assembled data profiles for all 52 samples are presented in Table 1 .
Validation and statistical analysis. While most apparent coinfections could be verified by serotype-specific PCR with independent primers, some could not (Table 1 ). Since two of the assays (microarray and Adenovirus Consensus kit) use detection signal amplification techniques that could render them more sensitive than traditional PCR/agarose gel visualization techniques, it is likely that these PCR-unverifiable signals are accurate. In the case of the microarray, the test is self-validating: the array tests for the presence of three physically distinct serotypespecific alleles from the E1A, hexon, and fiber genes. In other cases, the primary techniques tested here verified each other even when traditional PCR was unable to verify particular 
Discussion
This study unequivocally demonstrates a strong and significant association of adenoviral coinfections composed of multiple currently circulating pathogenic serotypes [as defined in (6) ⎯ HAdV-4, 7, 21, 3, and 14] with vaccine breakthrough (Tables 1 and 2 For example, the sequence homology relationships among HAdV-11, HAdV-35, HAdV-7, and HAdV-21 show that either HAdV-11 or HAdV-35 is a recombinant strain resulting from a fiber gene transfer between two of the other aforementioned strains (23) . HAdV-7 subtype 7h, a recently emerged and currently common pathogenic strain, has been shown to be an otherwise normal Ad7 with a recombined Ad3 fiber gene (22) . It has been suggested that HAdV-4 appears to be a recombinant between two species, essentially an HAdV-B with an HAdV-C-derived fiber protein (24) , though this result has been brought into question by recent whole-genome sequencing efforts (D. Seto, manuscript submitted). The currently dominant pathogenic HAdV, a considerably diverged variant HAdV-4 strain (2) appears to be a very recent recombinant between HAdV-4 and an HAdV-B1 serotype, probably 7 or 3 (D. Seto, manuscript in preparation). Given that these two are the most common coinfectants seen in our sample set, this raises the possibility that the observed dominance of coinfections during the period of vaccination may have contributed to the emergence of the new variant. Given the propensity of adenovirus to evolve through recombination, conditions that might favor symbiotic coexistence are of considerable concern.
Many identified coinfectants were strains not generally associated with ARD in the military. HAdV-C, though rarely associated with pharyngitis outbreaks in recruits (6) , is usually seen in children and can produce latent infections lasting into young adulthood (4). These latent infections can be revived in tissue cultures such as those used to amplify HAdV from the samples used in this study. The causal nature of the HAdV-B2 and HAdV-F species identifications with respect to ARD is also questionable. HAdV-B2 is primarily associated with urinary tract infections in immunocompromised patients (15) , though it is occasionally associated with gastroenteritis, pharyngoconjunctival fever, and ARD (1). HAdV-F is almost exclusively associated with gastroenteritis. The signals from these strains were invariably weak (as were most signals from HAdV-C) in comparison with the strong signals often seen from HAdV-B1 and HAdV-E.
Coinfections with these virus species (B2, F, C) did not correlate well with vaccination in any case, but results were included because these agents are capable of genetic complementation with upper respiratory strains (11, 25) , and serve to suggest the general complexity of the human adenoviral load. The question of whether these infections are latent or active parts of symbiotic coinfections (unassociated with vaccination) will have to wait for data collected from concurrent ill and healthy populations.
The HAdV vaccine (an enteric-coated live-virus tablet designed to transiently and selectively infect the gastrointestinal tract with normal respiratory HAdV strains) contained viable HAdV-4 and HAdV-7, so it must be asked whether the detected coinfectants arose from the vaccine itself or from community acquisition of currently circulating strains. Most HAdV-4 strains seen in this study are clearly not the vaccine strain, but rather a highly divergent variant (26) that appears to have recently replaced the vaccine strain. This was shown previously through sequence analysis of 1500 bp of the hexon gene (2) . These data were conclusive, as the variant HAdV-4 isolates consistently differ from the vaccine strain by 32 base substitutions (including 9 coding changes) in this region [see GenBank records associated with (2) and Table   1 ]. This variant, represented in GenBank by strain Z-G 95-873, is fourfold reduced in neutralization compared with the AV4 RI-67 prototype (essentially the vaccine strain) using anti- Hexon sequence analysis also revealed that many of the HAdV-7 coinfectants are HAdV7d2. These are distinguished from the HAdV-7 vaccine strain (HAdV-7a) by a single coding polymorphism in the hexon sequence, but this polymorphism [protein:L443Q, or nucleotide:T1328A in the GenBank records associated with (2) ] is specific to HAdV-7d and HAdV-7d2 and is not found in HAdV-7a, b, c, g or h, nor in the vaccine strain itself (2, 3, 27).
HAdV-7d2 has recently been reported as a circulating upper respiratory pathogen among both vaccinated military populations in the United States and among unvaccinated civilian populations in Japan (3, 28) , while outbreaks of the older subtypes (such as HAdV-7a) have become less common. One of the HAdV-7 coinfectant's hexon sequence was grouped with the highly divergent HAdV-7 prototype (HAdV-7p) (2) . Three of the other HAdV-7 coinfectants were shown to be HAdV-7h by fiber gene sequencing. The fiber gene of HAdV-7h appears to have been horizontally transferred from HAdV-3, and hence is highly diverged from the usual HAdV-7 fiber gene (as found in the vaccine strain) (22) . Still other coinfections contain HAdV-3 or HAdV-21 instead of (or in addition to) HAdV-7, and these coinfectants clearly did not come from the vaccine. Only one HAdV-7 from this collection shared an identical hexon sequence with the vaccine strain. The bulk of the evidence supports the idea that the coinfectants seen in this study did not arise from direct infection by the vaccine itself.
Three lines of evidence support the idea that most of the apparent genetic complexity in these samples comes from multiple independent strains, as opposed to recombinants with mixed genetic character. The first comes from the microarray data. The microarray tests for hybridization of three independent probes. These probes were designed to match strain-specific sequences in three genes (8) . Hence, hybridization of genes from one strain to the identifying probes for two strains would require the redundant presence of two different alleles in all three genes. Since both natural recombination in hosts (21, 22) However, this effort generated several sequences that did not fit into the assembled scaffold, despite its apparent completeness and consistency with a published HAdV-5 genome, GenBank accession number AY339865 (29) . These "orphan" sequences were subsequently identified as It is important to note that conventional clinical microbiological methods, including microneutralization and hemagluttination inhibition, are comparative and designed to identify the primary HAdV serotype (or species) present in a sample. Therefore, secondary infections are masked in these methods by nature of the tests themselves (for example, microneutralization is reported in terms of the strongest reaction, not the spectrum of reactions across all serotypes).
Likewise, the use of direct sequencing (2) and restriction enzyme analysis methods (30) are likely to restrict identification to a single strain, particularly if one coinfectant is numerically dominant. For the sake of comparison, it is satisfying that the predominant serotype or species signal generated in both the microarray and PCR-ELISA tests matched the results obtained from the original microneutralization experiments in every documented case. In terms of discerning coinfections, as opposed to primary single infections, all three molecular methods used here served their purpose. Each method revealed a similar correlation between multiplicity of infection and previous vaccination (Table 2) . Furthermore, the microarray analyses revealed several coinfections of multiple serotypes from the diverse HAdV-B1 subspecies (most commonly HAdV-7 and HAdV-3), coinfections that could not have been resolved by speciesspecific methods. In this context, the microarray provides a distinct advantage to traditional methods, one relevant to both single and multiple infections: HAdV-7 and HAdV-3 crossreact in neutralization assays because they share very similar hexon proteins, while HAdV-7h is misidentified as HAdV-3 by HI assays because they share very similar fiber proteins (31). The microarrays used here independently test for strain-specific differences in three different genes (hexon, fiber, and E1A), and can therefore resolve pairs with differences in only one of the three genes. This is important due to the potential role of recombination in strain evolution, since recombination is likely to generate strains like HAdV-7h that resemble one serotype at one locus but another serotype at another locus. HAdV-7h has become an epidemiologically important pathogen in recent years (22) .
In all but two vaccinated individuals testing positive for HAdV-7 by microarray (and one of the two unvaccinated HAdV-7-positive individuals), the HAdV-B strains present are either HAdV-7h [an HAdV-7/HAdV-3 recombinant (22)] or a combination of HAdV-7 with a marginally detectable HAdV-3. These two conditions may well represent different steps on the same path, the latter representing a coinfection with functional sharing of proteins and the former representing a unique strain (HAdV-7h) formed by recombination between the two original strains. Perhaps the combination of HAdV-7 and HAdV-3, by either recombination or by complementation in trans, allows partial avoidance of vaccine-induced immunity while retaining aspects of the HAdV-7 phenotype that make it a much more common agent of disease than is HAdV-3.
The vaccinated samples collected here (from 1996-1998) are not perfectly concurrent with the unvaccinated samples (collected from 1998-2000). Vaccination was done systematically, if at all; hence, vaccinated individuals tended to be sampled at times when all recruits were being vaccinated, and vice versa. It is possible that the phenomenon of coinfection documented here is temporally correlated rather than being related to vaccination, though it would seem highly unlikely that a vaccination-independent event would be so tightly correlated with the termination of the vaccination program. Furthermore, the change from HAdV-4/HAdV-7 coinfections to HAdV-4 monoinfections (rather than a shift between strains) would be unusual in the absence of a shift in selective pressure. The reintroduction of the vaccine in the next few years will allow further examination of the relationship between vaccination and coinfection.
Whether coinfections are composed of multiple circulating pathogens, retained vaccine strains, or latent strains revived by the primary infection, they represent an optimal condition for the generation of new, potentially virulent, and uniquely selectable recombinant variants. Since these sorts of variants appear to play a major role in the evolution of new pathogenic strains of HAdV (1, 16, 22) , the control of situations that enable or promote recombination should be a significant consideration. If coinfection-derived HAdV-4 and HAdV-7 are immunologically distinct from independently grown HAdV-4 and HAdV-7, then vaccine protection against coinfections might be achieved by vaccination with coinfection-derived viral mixtures.
Methods
Sample collection and preparation. Samples were collected as throat swabs in viral transport medium from military recruits suffering from FRI at a variety of training camps as previously described (2) . The throat swab samples were cultured on A549 cells, tested with traditional serological methods, and both the original swabs and the ITCF samples were stored at -80°C.
Samples initially testing positive for HAdV-4 or HAdV-7 by culture and serotype-specific Ab neutralization were chosen for analysis and grouped by previous vaccination status. DNA extracts obtained from ITCF samples were collected and used in the molecular assays conducted in this study. Collection details and symptomological definitions were previously published (2) and sample details are listed in Table 1 .
The first 13 of 52 samples sent by NHRC for testing by Naval Research Laboratory (NRL) personnel were tested in a masked fashion (i.e., the vaccination status of the individuals from which these samples came were unknown to NRL personnel). The study was expanded to include all 52 samples, as used in a previous study (2) after the initial tests and subsequent unmasking revealed a high rate of respiratory HAdV coinfection, primarily in vaccinated individuals.
To control for the introduction of contaminating or coinfecting adenoviral strains during tissue culture, five original throat swab samples (vaccinated) were directly tested for the presence of coinfectants using serotype-specific PCR and microarray analyses (see Table 1 ). Although sensitivity of detection, on average, was lower in original specimens (as expected, since tissue culture greatly increases titer), coinfections were still detectable.
Microarray-based genotyping. One µl of purified DNA extract from each of the 52 ITCF samples was used as the template in 50 µl degenerate PCR amplification reactions. The primers, degenerate PCR amplification protocol, probes, and microarray fabrication techniques have been previously documented (8) . Once constructed, the spotted microarrays were blocked with a 3% bovine serum albumin-casein solution (BSA-C) for 15 min at room temperature and the slides were outfitted with MAUI Mixer DC hybridization chambers (BioMicro Systems, Salt Lake City, Utah, USA). Twenty µl hybridization reactions (13.6 µl biotinylated degenerate PCR amplicons, 2 µl 3% BSA-C, 4 µl 20X SSC, and 0.4 µl 10% SDS) were denatured for 3 min at 98°C and immediately applied to the microarrays. Hybridizations were performed for 2 hours at 63°C on a MAUI Hybridization System (BioMicro Systems). Post-hybridization, slides were washed twice with 4X SSC-0.2% SDS buffer for 3 min at 63°C and twice with 2X SSC buffer for 1 min at room temperature. Hybridization events were detected by the sequential addition of Adenovirus-specific PCR. The species-specific PCRs were done using the primers described in (9) and the Qiagen Multiplex PCR Kit (Qiagen, Valencia, California, USA) as per the PCR kit instructions (with .5X Q solution). These PCRs were done in 25 µl reaction volumes with a 52ºC annealing temperature. In general, PCR reactions were run on an iCycler (Bio-Rad Laboratories, Hercules, California, USA) and analyzed on 1.5% agarose gels. We used both a standard DNA ladder and an in-house ladder composed of a multiplex PCR reaction containing DNA from all six species as size standards. Monoplex PCR was performed under identical reaction conditions, except that primers were used in independent reactions. Sequencing reactions and microneutralizations were performed as in (2) . Strain-specific PCRs for verification (see Table 1 ) were done, when possible, in the manner described in the publications to which they are referenced (Table 3) , with occasional substitutions of polymerase type and annealing temperature adjustments.
Statistical analysis. For each of the four molecular methods tested (microarray, Adenovirus
Consensus kit, species-specific multiplex PCR, and serotype/species-specific monoplex PCR) the total numbers of strains identified in each vaccinated (N = 21) and unvaccinated (N = 31) sample isolate were enumerated. Using these numbers, we performed the Fisher exact test using SAS software (Version 9.0, SAS Institute, Inc., Cary, North Carolina, USA) to compare the distributions of coinfectant counts in the two populations.
